{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:49Z","timestamp":1791915889943,"version":"4.3.4"},"reference-count":76,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/17460441.2025.2482058","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T22:20:10Z","timestamp":1742422810000},"page":"405-417","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa"],"prefix":"10.1080","volume":"20","author":[{"given":"Klaudia","family":"Knecht-Gurwin","sequence":"first","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Matusiak","sequence":"additional","affiliation":[{"name":"4 Military Hospital","place":["Wroclaw, Poland"]},{"name":"Wroclaw University of Science and Technology","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"4 Military Hospital","place":["Wroclaw, Poland"]},{"name":"Wroclaw University of Science and Technology","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1301"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16691"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0201"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.05.004"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.5114\/dr.2024.140820"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111365"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-023-00295-2"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13449"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20067"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.033"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.036"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14619"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.021"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12083"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2800"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03465.x"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.004"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080218"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.11.018"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.042"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.08.018"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041275"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14034"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42595-z"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0141"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_3_4_34_1","unstructured":"U.S. Food and Drug Administration. Pharmacology review: secukinumab (cosentyx). 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125504Orig1s000MedR.pdf"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12110"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314904"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.09.021"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-EWRR2019.77"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0031-5"},{"key":"e_1_3_4_40_1","unstructured":"Novartis Pharmaceuticals Corporation. Secukinumab (AIN457) U.S. Food and drug administration report. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125504s073lbl.pdf"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.876"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S105263"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12710"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14155"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17822"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"e_1_3_4_48_1","unstructured":"ClinicalTrials.gov. A randomized withdrawal extension study of secukinumab to demonstrate long-term efficacy safety and tolerability in subjects with moderate to severe hidradenitis suppurativa. ClinicalTrials.Gov identifier NCT04179175. 2024. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04179175"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae098"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17178"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00906-2"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18685"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16605"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.05.015"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.3655"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S449367"},{"key":"e_1_3_4_59_1","unstructured":"Novartis Pharmaceuticals. Long term observational study to collect in a real-world population data on the treatment pattern of secukinumab in adult patients with moderate to severe hidradenitis suppurativa. ClinicalTrials.Gov identifier NCT05921994. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05921994"},{"key":"e_1_3_4_60_1","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): COSENTYX\u00ae (secukinumab). Application number: 125504Orig1s000. Novartis pharmaceuticals corporation. 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125504Orig1s000ClinPharmR.pdf"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50013-7"},{"key":"e_1_3_4_65_1","unstructured":"European Medicines Agency. Cosentyx (secukinumab): summary of product characteristics. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00675-w"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927"},{"issue":"11","key":"e_1_3_4_69_1","first-page":"1365","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"15","author":"Balzola F","year":"2012","unstructured":"Balzola F, Cullen G, Ho GT, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Inflamm Bowel Disease Monit. 2012;15(11):1365.","journal-title":"Inflamm Bowel Disease Monit"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010095"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01616-1"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20234"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102450"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad345"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040801"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S418748"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19252"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2025.2482058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T18:13:05Z","timestamp":1743531185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2025.2482058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/17460441.2025.2482058"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2025.2482058","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}